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Abstract
Background: Diabetes is associated with changes in myocardial stress-response pathways and is recognized as an
independent risk factor for cardiac remodeling. Using spontaneously diabetic Goto Kakizaki rats as a model of type
2 DM we investigated whether post-translational modifications in the Akt - FOXO3a pathway, Sirt1 - p53 pathway
and the mitogen activated protein kinase p38 regulator are involved in post-infarct cardiac remodeling
Methods: Experimental myocardial infarction (MI) was induced by left anterior descending coronary artery ligation
in spontaneously diabetic Goto-Kakizaki rats and non-diabetic Wistar controls. Cardiac function was studied by
echocardiography. Myocardial hypertrophy, cardiomyocyte apoptosis and cardiac fibrosis were determined
histologically 12 weeks post MI or Sham operation. Western blotting was used to study Caspase-3, Bax, Sirt1,
acetylation of p53 and phosphorylation of p38, Akt and FOXO3a. Electrophoretic mobility shift assay was used to
assess FOXO3a activity and its nuclear localization.
Results: Post-infarct heart failure in diabetic GK rats was associated with pronounced cardiomyocyte hypertrophy,
increased interstitial fibrosis and sustained cardiomyocyte apoptosis as compared with their non-diabetic Wistar
controls. In the GK rat myocardium, Akt- and FOXO3a-phosphorylation was decreased and nuclear localization of
FOXO3a was increased concomitantly with increased PTEN protein expression. Furthermore, increased Sirt1 protein
expression was associated with decreased p53 acetylation, and phosphorylation of p38 was increased in diabetic
rats with MI.
Conclusions: Post-infarct heart failure in diabetic GK rats was associated with more pronounced cardiac
hypertrophy, interstitial fibrosis and sustained cardiomyocyte apoptosis as compared to their non-diabetic controls.
The present study suggests important roles for Akt-FOXO3a, Sirt1 - p53 and p38 MAPK in the regulation of post-
infarct cardiac remodeling in type 2 diabetes.
Background
Diabetes increases the risk for fatal myocardial infarc-
tion and development of heart failure [1-3]. The poor
prognosis after myocardial infarction has been
explained by the underlying diabetic cardiomyopathy
exacerbated by other factors such as hypertension and
ischemic heart disease. Several factors such as insulin
resistance and enhanced tissue renin-angiotensin sys-
tem activity presumably also contribute to the patho-
genesis [4-6]. Earlier studies have provided evidence
that diabetes is associated with enhanced susceptibility
to cardiomyocyte apoptosis and fibrosis which, in turn,
could interfere with the post-infarct cardiac remodel-
ing process. Hyperglycemia causes the build-up of
reactive oxygen species (ROS) and reactive nitrogen
species (RNS) which in turn induces p53- and cyto-
chrome-c mediated caspase-3-dependent apoptosis
[7-10]. Accordingly, myocardial cell death in diabetes
has been prevented by the use of antioxidants and cas-
pase inhibitors indicating a causal role for apoptosis in
the pathogenesis of diabetes-induced cardiomyocyte
loss [11]. * Correspondence: eero.mervaala@helsinki.fi
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hypertrophy and interstitial fibrosis in spontaneously
diabetic Goto-Kakizaki (GK) rats, a non-obese model of
type II diabetes [12], Wistar rats were used as controls.
To date there is lack of evidence concerning the invol-
vement of stress response pathways and their role in
MI-induced cardiac remodeling in diabetes. In this
study we examined the roles of the Sirt1-p53 pathway,
Akt-FOXO3a pathway and the p38 MAPK within the
scope of MI-induced acceleration of cardiac remodeling
in the diabetic heart. Sirtuin1 (Sirt1), a class III histone
deacetylase (HDAC) has been shown to act as an endo-
genous inhibitor of apoptosis in cardiac myocytes [13]
and Sirt1-mediated deacetylation of DNA-bound his-
tones, p53 and forkhead class O 3a (FOXO3a) have
been implicated in the inhibition of apoptosis and pro-
motion of cellular growth [14], our previous study
showed that Sirt1 is overexpressed in cardiomyocytes of
diabetic Goto-Kakizaki rats [15]. The protein kinase B
(PKB or Akt) has been identified as an important effec-
tor of the insulin/IGF - PI3K signaling pathway, acting
as a regulator of cell survival and promoting cardiac
hypertrophy [16-19]. FOXO3a transcription factor is
negatively regulated by Akt, and in the absence of Akt-
mediated phosphorylation FOXO3a has been shown to
induce the expression of genes implicated in the apopto-
tic process [20]. Mitogen activated protein kinase
(MAPK) p38 is activated after ischemic events and
angiotensin II [21-23]. Long-term p38 MAPK activation
has been shown to increase cardiac hypertrophy, fibrosis
and apoptosis suggestive of a deleterious effect on the
h e a r t[ 2 4 - 2 6 ]a n dp 3 8M A P Ko v e r e x p r e s s i o nh a sb e e n
shown to induce proinflammatory and profibrotic genes
[27].
In the present study we examined whether the under-
lying diabetic pathology was exacerbated by experimen-
tal MI. In particular we wanted to investigate whether
MI-induced cardiomyocyte hypertrophy, apoptosis and
interstitial fibrosis was associated with changes in Akt -
FOXO3a phosphorylation, Sirt1 - p53 deacetylation and
p38 MAPK phosphorylation.
Methods
Myocardial infarction, blood pressure recordings and
sample preparations
The investigation conforms to the Guide for the care
and use of laboratory animals published by the US
National Institutes of Health (NIH Publication No. 85-
23, revised 1996). Experimental myocardial infarction
was induced by ligating the left anterior descending
(LAD) coronary artery in 23 eight-week old sponta-
neously diabetic Goto-Kakizaki rats (M&B, Denmark)
(GK + MI) and 17 age-matched non-diabetic Wistar
(M&B, Denmark) (W + MI) rats as described previously
[28] under ketamine (50 mg/kg, i.p.) and medetomidine
(10 mg/kg, i.p.) anesthesia. Long-acting insulin (1 IU/
rat) was given two hours before anesthesia to GK rats to
prevent hyperglycemia. The rats received postoperative
pain reliever (buprenorphine 0.01-0.05 mg/kg s.c.) twice
a day for two consecutive days. Sham-operated Goto-
Kakizaki rats (GK) (n = 8) and Wistar rats (W) (n = 9)
served as controls. 24 hours after surgery 8 GK rats
were alive (GK + MI) and 10 Wistar rats were alive (W
+ MI). Systolic blood pressure was measured using a tail
cuff blood pressure analyzer (Apollo-2AB Blood Pres-
sure Analyzer, Model 179-2AB, IITC Life Science,
Woodland Hills, CA, USA) at week 12. Urine samples
were collected over a 24 h period in metabolic cages for
catecholamine measurements using 1 M HCl as a pre-
servative. Rats were anesthetized with CO2/O2 (AGA,
Riihimäki, Finland) and decapitated. Blood samples were
collected for biochemical measurements using EDTA as
an anticoagulant. The hearts were excised, washed with
ice-cold saline, blotted dry, weighed, and snap-frozen in
liquid nitrogen or isopentane (-35°C). All samples were
stored at -80°C until assayed.
Echocardiography
Transthoracic echocardiography (Toshiba Ultrasound,
Japan) was performed on all rats under isoflurane
anesthesia (AGA, Riihimäki, Finland) in a blinded fash-
ion by the same technician during the last study week.
Each animal underwent three separate measurements by
detaching the transducer between each measurement,
and three pictures were taken. Parameters needed for
the calculation of cardiac function and cardiac dimen-
sions were measured from three systole-diastole cycles.
By a two-dimensional imaging method (Teichholz
method), using a 15-MHz linear transducer a short axis
view of the left ventricle at the level of the papillary
muscles was obtained. Two-dimensionally guided M-
mode recording through the anterior and posterior walls
of the left ventricle let us measure the left ventricle (LV)
end-systolic (LVESD) and end-diastolic (LVEDD)
dimensions as well as interventricular septum (IVS),
anterior wall (AW) and posterior wall (PW) thickness.
LV fractional shortening (FS) and ejection fraction (EF),
measures of LV systolic function, were calculated from
the M-mode LV dimensions using the following equa-
tions:
FS LVEDD-LVESD LVEDD %{ ( ) / }  100
EF LVEDV)-(-LVESV LVEDV %{ ( ) / }  100
where LVEDV is the LV end-diastolic volume, equal
to (7 × LVEDD
3)/(2.4+(LVEDD) and LVESV is the LV
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3)/(2.4
+(LVEDS). Cardiac output (CO) was calculated as a pro-
duct of heart rate (HR) and stroke volume (SV =
LVEDV-LVESV). CO (ml/min) = HR × SV.
Infarct size, collagen volume fraction and cardiomyocyte
cross sectional area
For histological analysis the hearts were fixed in 10% buf-
fered formalin solution. Transversal sections of the left
ventricle were embedded in paraffin and 5 μm-thick sec-
tions were cut and stained with Masson’s trichrome or
picrosirius red. The infarct sizes were determined plani-
metrically from the trichrome-stained histological sec-
tions as described previously [29]. In brief, the presence
of collagen scars compatible with an old infarction was
analyzed by examination of transverse LV sections. The
size of MI was determined planimetrically as the ratio of
infarct tissue or scar to the length of the entire LV endo-
cardial circumference. Interstitial collagen volume frac-
tion from the remote area was measured from picrosirius
red-stained histological sections by light microscopy
(×200) using computerized software (ImageJ, NIH). Con-
ventional light microscopy at ×400 magnification was
used to determine cardiomyocyte cross sectional area. 9-
12 random fields from the remote area spanning the left
ventricular septal wall were studied, and in each field the
cell borders were measured from myocytes cut in short
axis with a visible nucleus. An average of 60 cardiomyo-
cytes per animal (n = 6) from each study group were stu-
died. Cross sectional area was evaluated in a blinded
fashion and analyzed using the ISI imaging software
(Image Solutions Inc., Whippany NJ, USA).
Immunohistochemistry
For immunohistochemistry, formalin-fixed myocardial
sections were deparaffinized and rehydrated as described
in detail previously [30]. Primary polyclonal antibody
against Sirt1 (Sir2alpha, Rabbit polyclonal, Upstate;
1:200 dilution) and secondary biotinylated anti-rabbit
antibody (Vector Laboratories Inc., California, USA)
were used. The average percentages of Sirt1-positive
cardiomyocytes/total number of cardiomyocytes were
calculated from 6 separate fields of transverse left ven-
tricular tissue sections using light microscopy (×400
magnification).
Biochemical Analyses
Blood glucose was determined with a handheld test
meter (Glucocard II®, Arkray, Japan), plasma BNP (BNP-
45, Peninsula Laboratories, Belmont, CA, USA), plasma
renin activity (Angiotensin I RIA kit, Diasorin, Italy),
serum aldosterone (Coat-a-Count Aldosterone RIA kit,
DPC Biermann, Bad Nauheim, Germany) and serum
insulin (Rat insulin RIA kit, Linco, St. Charles, Missouri,
USA) were determined by radioimmunoassay according
to the instructions of the manufacturers. Urinary nora-
drenalin was analyzed using the isocratic ion-pair
reversed-phase high-performance liquid chromatography
method with electrochemical detection [31].
TUNEL Apoptosis Assay
Cardiomyocyte apoptosis was assessed by the terminal
deoxynucleotide transferase mediated ddUTP nick end
labeling (TUNEL) assay as previously described [32]. In
brief, apoptotic nuclear DNA strand breaks were end-
labeled with digoxigenin-conjugated dideoxy-UTP by
terminal transferase and visualized immunohistochemi-
cally with digoxigenin antibody conjugated to alkaline
phosphatase. The assay was standardized with the use
of adjacent tissue sections treated with DNase I to
induce DNA fragmentation as a positive control for
apoptosis. The proportion of TUNEL-positive cardio-
myocytes was calculated from transverse left ventricular
tissue sections using light microscopy (×200 magnifica-
tion) with an ocular grid. Cardiomyocyte origin of the
apoptotic cells was identified by the presence of myofi-
laments surrounding the nucleus. The proportion of
apoptotic cardiomyocytes was counted in the border
zones of infarct scars and in the remote non-infarct
myocardium [28].
Immunoblotting
Myocardial samples from left ventricles of MI - and
Sham-operated GK and Wistar rats were electrophore-
tically separated by SDS-PAGE (20 μg total protein per
lane). Proteins were transferred to a PVDF membrane
( I m m o b i l o n - P R ,M i l l i p o r e ,B e d f o r d ,M A ,U S A )a n d
blocked in 5% non-fat milk-TBS - 0.01% Tween-20R
buffer. The membranes were probed with the following
antibodies: anti-caspase-3 (Upstate-Millipore), anti-Bax
(Abcam) anti-phospho-FKHRL/FOXO3a (Cell Signal-
ing Technologies), anti-FKHRL/FOXO3a (CST), anti-
Akt (CST), anti-phospho-Akt (CST), anti-p38 (CST)
and anti phospho-p38 (CST). Tubulin was used as
loading control (Anti-alpha tubulin, Abcam, Cam-
bridge, UK). Horseradish peroxidase-conjugated anti-
rabbit secondary antibody (Chemicon) was subjected
to enhanced chemiluminescence solution (ECL plus,
Amersham Biosciences, Buckinghamshire, UK) and
exposed to x-ray film (Hyperfilm-ECL, Amersham).
We quantified the relative protein expression in sepa-
rate samples from the x-ray film by densitometry
(Synoptics, Cambridge, UK).
Electrophoretic Mobility Shift Assay of Nuclear FOXO3a
Transcription Factor
Electrophoretic mobility shift assay (EMSA) was used
to determine DNA-binding of nuclear FOXO3a
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g r i n d i n gl e f tv e n t r i c l es a m p l e sf r o mt h er e m o t ea r e ai n
liquid nitrogen and incubating in a buffer with protease
inhibitor (Complete®, Roche), membrane proteins were
solubilized with Nonidet P-40 (Roche Diagnostics
GmBH, Mannheim, Germany). 5 μg of nuclear extracts
were incubated in binding buffer (3 mM Tris pH 7.5, 50
mM NaCl, 5% Glycerol, 1 mmol/l EDTA, 0.01 mg/ml
Poly [d(I-C)], 1 mmol/l DTT, 2 mg/ml BSA) and 1.25
fmol of digoxigenin-tagged FOXO3a oligonucleotides:
5’-DIG-ATT GCT AGC AAG CAA AAC AAA CCG
CTA GCT TA-3’ and 5’-DIG-TAA GCT AGC GGT
TTG TTT TGC TTG CTA GCA AT-3’ (Oligomer, Hel-
sinki, Finland). After 30’ incubation, the samples were
electrophoretically separated by 5% SDS-PAGE and
blotted to a nylon membrane (Hoefer semiPhor, TE77,
Amersham Biosciences). Nuclear proteins were cross
linked to the membrane for 10’ in 254 nm UV-light.
The membrane was probed with rabbit Anti-digoxi-
genin-AP-conjugate (Roche)f o r3 0m i n .a n di n c u b a t e d
in detection reagent (CDP Star, Roche) and exposed to
an x-ray film (Kodak Inc., Japan). The indication reac-
tion was done by incubating the samples with tagged
and untagged oligonucleotides and probing with rabbit
anti-FKHRL1 (sc-11351, Santa Cruz, CA, USA).
Quantitative real-time RT-PCR
Total RNA from the rat hearts were extracted with Tri-
zol® (Gibco, Invitrogen, Carlsbad, CA, USA), treated with
DNAse 1 (Deoxyribonuclease 1, Sigma Chemicals Co., St
Louis, MO, USA) and reverse transcribed to cDNA by
reverse transcription enzyme (Enhanced avian HS RT-
PCR kit, Sigma Chemicals Co, Saint Louis, MO, USA).
One μl of cDNA was subjected to quantitative real time
polymerase chain reaction using the Lightcycler® instru-
ment (Roche diagnostics, Neuilly sur Seine, France) for
detection of atrial natriuretic peptide (ANP), connective
tissue growth factor (CTGF), interleukin-6 (IL-6) and
ribosomal 18S mRNA. The following primers were used:
ANP forward CCGATAGATTCTGCCCTCTTGAA,
reverse CCCGAAGCAGCTTGATCTTC; CTGF forward
GGCAGGGCCAACCACTGTGC, reverse CAGTGC
ACTTGCCTGGATGG; IL-6 forward AGGAAGGCAG
TGTCACTCATTGT, reverse CTTGGGTCCTCATCC
TGGAA and 18S forward ACATCCAAGGAAGGCA
GCAG reverse TTTTCGTCACTACCTCCCCG. The
samples were amplified using FastStart DNA Master
SYBR Green 1 (Roche diagnostics) according to the pro-
tocol of the manufacturer.
Statistical analyses
Data are presented as means ± SEM. Statistically signifi-
cant differences in mean values were tested by analysis
of variance (ANOVA) and the Neuman-Keul’sp o s t - h o c
test for comparisons of multiple groups.
Results
Post-infarct heart failure in spontaneously diabetic Goto-
Kakizaki rats
24-hour survival after MI was 35% in Goto-Kakizaki rats
and 55% in Wistar rats. One rat (in the Wistar + MI
group) died during the follow-up period. At the end of
the 12-week follow-up there were no differences in
myocardial infarct size between GK + MI or Wistar +
MI rats as assessed by planimetry (Figure 1). In both
animal strains myocardial infarction led to thinning of
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Figure 1 Effect of myocardial infarction (MI) in diabetic Goto-Kakizaki (GK) rats and Wistar (W) rats 12 weeks after MI or Sham–
operation. (A) shows picrosirius–red stained whole heart section images (upper panels) and 600 ms from representative M-mode echocardiography
(lower panels), (B) shows infarction area measured by planimetry from picrosirius–stained slides. Data is presented as means ± SEM.
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as shown by decreased ejection fraction and fractional
shortening (Table 1). MI reduced systolic blood pressure
by 10 mmHg in Wistar and 19 mmHg in GK rats, systo-
lic blood pressure was slightly higher in sham-operated
GK rats (by 5 mmHg) (Table 1). All GK rats were
hyperglycemic and GK + MI rats showed increased
serum insulin concentration, all basic biochemical para-
meters are given in table 2.
Exacerbation of cardiomyocyte hypertrophy after MI in
diabetic Goto-Kakizaki rats
MI induced an increase in average cardiomyocyte size
(1.4-fold in GK) as evaluated from cross sections of left
ventricular tissue (Figure 2). Although MI also increased
cardiomyocyte cross sectional area in non-diabetic Wis-
tar rats, the average cardiomyocyte size in post-MI Wis-
tar rats was comparable to sham-operated GK rats
(Figure 2B). MI tended to increase ANP mRNA expres-
sion in Wistar and GK rats (Figure 2D).
Sustained cardiomyocyte apoptosis and increased
interstitial fibrosis after MI in the diabetic Goto-Kakizaki
rat heart
Post-infarct cardiomyocytea p o p t o s i sw a sa s s e s s e db y
TUNEL staining. In agreement with previous studies
[28], cardiomyocyte apoptosis was >10-fold higher in the
border zone compared to the non-infarct remote area
after MI both in diabetic and non-diabetic rats (Figure 3).
TUNEL analysis showed that the number of apoptotic
nuclei, measured from the border zone and in the area
remote to the infarct, was higher in GK rats after MI as
compared to Wistar controls (Figure 3). Sham-operated
GK rat cardiomyocytes did not show overt apoptosis.
Western blots revealed increased myocardial caspase-3
p r o t e i ne x p r e s s i o ni nG Kr a t sa f t e rM I .I n c r e a s e dB a x
protein expression was noted in both sham- and MI-
operated GK rats, in Wistar however, MI induced an
increase in Bax protein expression (Figure 3D). Intersti-
tial collagen volume fraction measured from the remote
area was increased in GK rats with MI compared to non-
diabetic Wistar rats with MI (Figure 4).
Akt - FOXO3a-dephosphorylation and FOXO3a-activation
in diabetic Goto-Kakizaki rats after MI
Our results showed that MI increased myocardial PTEN
p r o t e i ne x p r e s s i o ni nG Kb u tn o ti nW i s t a rr a t s( F i g u r e
5A). Phosphorylation of Akt kinase was decreased in GK
rat hearts 12 weeks post MI compared to post-MI Wistar
rats (Figure 5B). The phosphorylation status of Akt-regu-
lated FOXO3a transcription factor was decreased in
sham- and MI GK rats and MI Wistar rats (Figure 5C).
Furthermore, the examination of DNA-bound FOXO3a
by electrophoretic mobility-shift assay demonstrated a
marked increase in nuclear, DNA bound FOXO3a in GK
rats with MI compared to Sham-GK and corresponding
post-MI Wistar controls (Figure 5D).
Sirt1 Protein Overexpression and p53-Deacetylation in
the Goto-Kakizaki rat Heart after MI
We examined myocardial Sirt1-, acetyl-p53- and
p53 protein expression by western blotting and Sirt1-
localization by immunohistochemistry. Western blotting
showed an increase in Sirt1 protein expression in sham-
operated GK rats compared to Wistar with no further
increase in Sirt1 protein expression after MI (Figure 6A).
Immunohistochemical analysis revealed an increase in
the number of Sirt1-positive nuclei in the infarct area of
Table 1 Systolic blood pressure and echocardiography data in diabetic Goto-Kakizaki (GK) rats and non-diabetic
Wistar (W) rats 12 weeks post myocardial infarction (MI) or Sham operation, (d) denotes diastole and (s) systole.
W Sham
(n = 9)
GK Sham
(n = 8)
W+M I
(n = 9)
GK + MI
(n = 8)
Systolic blood pressure (mmHg) 144 ± 7.9 149 ± 6.2 135 ± 5.4*
# 131 ± 14*
#
Anterior wall thickness (d), (mm) 1.8 ± 0.2 1.8 ± 0.3 1.3 ± 0.6 1.5 ± 0.7
Anterior wall thickness (s), (mm) 3.1 ± 0.1 3.1 ± 0.1 1.7 ± 0.4*
# 1.9 ± 0.4*
#
LV inner diameter (d), (mm) 8.6 ± 0.5 7.9 ± 0.6 10.4 ± 1.1*
# 10.0 ± 1.7
#
LV inner diameter (s), (mm) 5.0 ± 0.2 4.4 ± 0.3 8.5 ± 0.7*
# 8.3 ± 0.8*
#
Posterior wall thickness (d), (mm) 1.9 ± 0.2 2.1 ± 0.2 2.3 ± 0.4 2.1 ± 0.6
Posterior wall thickness (s), (mm) 3.1 ± 0.1 3.2 ± 0.1 2.9 ± 0.2 2.5 ± 0.2
End-diastolic volume, (ml) 1.4 ± 0.2 1.1 ± 0.2 2.3 ± 0.6*
# 2.2 ± 0.9*
#
End-systolic volume, (ml) 0.3 ± 0.03 0.2 ± 0.03 1.52 ± 0.27*
# 1.4 ± 0.3*
#
Heart rate, (min
-1) 341 ± 26 360 ± 29 346 ± 19 302 ± 60
#
Ejection fraction (%) 77.9 ± 1.9 80.5 ± 2.3 39.7 ± 7.7*
# 41.6 ± 6.9*
#
Fractional shortening (%) 42.3 ± 1.7 45.3 ± 2.7 18.9 ± 4.2*
# 19.1 ± 3.9*
#
Cardiac Output (ml/min) 368 ± 18.8 321 ± 23.7 258 ± 39.6* 228 ± 21.9*
The data is presented as means ± SEM.
* denotes P < 0.05 vs. W Sham,
#P < 0.05 vs. GK Sham,
†denotes P < 0.05 vs. W + MI.
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ferred site was decreased in the LV remote area in post-
MI GK rats compared to GK sham and post-MI Wistar
rats (Figure 6D) as assessed by western blotting.
Increased p38 MAP kinase phosphorylation in diabetic GK
rats after MI
Protein expression of myocardial p38 was increased after
MI in Wistar rats (Figure 7A). However, the phosphory-
lation of p38 MAPK was increased only in post-MI GK
rats (Figure 7B). The mRNA expressions of p38-
regulated, profibrotic connective tissue growth factor
(CTGF) and proinflammatory interleukin -6 (IL-6)
tended to be increased in post-MI GK rats (Figure 7C-D).
Discussion and Conclusions
Underlying cardiomyopathy has been attributed to an
increase in mortality and morbidity after myocardial
infarction in patients with diabetes. This study was con-
ducted to investigate the molecular mechanisms of post-
infarct cardiac remodeling, specifically the regulators
involved in cell survival and apoptosis. Our study
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Figure 2 Left ventricular hypertrophy is accentuated in the spontaneously diabetic Goto-Kakizaki (GK) rat after MI. In (A) the normal
distribution curves are shown of cardiomyocyte cross sectional areas (μm
2) calculated from an average of 400 cardiomyocytes in each group (N
= 6 per group). The mean values, presented as μm
2 of cardiomyocyte cross sectional areas, calculated from the total number of myocytes are
presented in (B). Panel (C) shows the heart weight/body weight ratios (g/kg) and panel (D) shows the ANP mRNA expression as determined by
qRT-PCR form the LV:s of GK and Wistar rats (N = 6). Data is presented as means ± SEM; * indicates P < 0.05 vs. W (sham-operated Wistar),
#
indicates P < 0.05 vs. GK (sham-operated GK),
† indicates P < 0.05 vs. W+MI.
Table 2 Basic biochemical parameters 12 weeks after MI- or sham operation in spontaneously diabetic Goto-Kakizaki
(GK) and non-diabetic Wistar (W) rats.
W Sham
(n = 9)
GK Sham
(n = 8)
W+M I
(n = 9)
GK + MI
(n = 8)
B-Glucose (mmol/l) 4.9 ± 0.24 8.2 ± 0.78* 4.2 ± 0.67 8.2 ± 0.10*
†
S-Insulin (pg/ml) 1.7 ± 0.58 2.2 ± 0.19 1.2 ± 0.24 3.3 ± 0.10*
†
P-Renin activity (ng/ml/h) 2.5 ± 0.24 2.1 ± 0.43 3.6 ± 0.43 1.9 ± 0.48
†
S-Aldosterone (pg/ml) 91.8 ± 17.6 194 ± 27.3 171 ± 52.2 262 ± 23.3*
U-Noradrenaline (nmol/24 h) 4.5 ± 0.46 3.0 ± 0.27 6.0 ± 0.38
# 4.5 ± 0.39
†
The data are presented as means ± SEM.
* denotes P < 0.05 vs. W Sham,
#P < 0.05 vs. GK Sham and
†P < 0.05 vs. W + MI.
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occlusion of the left ascending coronary artery than the
control non-diabetic Wistar rats. The remaining animals
survived the follow-up period, and at the 12-week cut-
off point significant remodeling in the remaining, viable
tissue of the heart had occurred. At 12 weeks post-MI,
there were no significant differences in echocardiogra-
phy parameters indicating that the samples were taken
before decompensated heart failure. Earlier studies have
shown that GK rats develop spontaneous impairment in
systolic function [15] whereas others have shown the
absence of overt systolic dysfunction at baseline in dia-
betic GK rats compared to Wistar [33]. Further accel-
eration in heart failure progression has been shown to
occur 8 weeks postligation in GK rats [33]. Our study
showed that baseline systolic function was similar
between the Wistar and GK strains, and that MI
induced a similar decrease in systolic function in dia-
betic and non-diabetic rats at the 12-week follow-up
point. In diabetic rats there was however an ongoing
exacerbation of post-infarct remodeling, such as
increased cardiomyocyte hypertrophy, a sustained
increase in cardiomyocyte apoptosis both at the remote
and border zone of the infarct, and a slight increase in
collagen deposition, evident 12 weeks postligation. The
post-MI changes in non-diabetic rats included an
increase in cardiac hypertrophy, an increase in cardio-
myocyte apoptosis only at the border zone, and no
changes in myocardial fibrosis. These macroscopic dif-
ferences between the animal strains were associated
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Page 7 of 13with pronounced molecular changes in stress response
pathways involved in cardiomyocyte hypertrophy, apop-
tosis and interstitial fibrosis in diabetic rats. Key changes
in the posttranslational modification and expression of
stress response proteins were decreased Akt phosphory-
lation and a concomitant increase in FOXO3a activa-
tion. Secondly, our results showed that Sirt1 protein was
overexpressed in the myocardial tissue of GK rats and
that one of the key Sirt1- targets; p53 was deacetylated
in the diabetic heart compared to the non-diabetic situa-
tion. In the present study our results further showed
that another Sirt1- target, FOXO3a was dephosphory-
lated, possibly due to Akt-kinase dephosphorylation in
the diabetic GK rat heart. Thirdly, p38 MAPK protein
phosphorlyation was increased in GK rats postligation.
Myocardial infarction leads to long-term functional
changes in the left ventricle by altering the topography
of infracted as well as non-infarct regions [34,35].
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Page 8 of 13Infarct scarification and ventricular dilatation produces
a mixture of pressure and volume overload in the non-
infarcted region of the left ventricle [36]. The long-
term effects of this pathological state includes ventri-
cular remodeling where individual cardiomyocytes
undergo maladaptive growth, ultimately leading to
apoptosis, or adaptive growth which leads to compen-
satory hypertrophy of the ventricle [37]. After MI,
exacerbation of hypertrophy occurs as a compensatory
mechanism of remaining, functional left ventricular tis-
sue to restore cardiac output [38]. In the present
study, MI exacerbated hypertrophy in both Wistar and
GK rats. As with our previous studies [15], pro-
nounced cardiac hypertrophy was found in non-infarct
GK rats compared to Wistar, which might be
explained partly by the modest increase (+5 mmHg) in
systemic blood pressure. Left ventricular hypertrophy
was associated with an increase in ANP expression and
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Page 9 of 13low plasma renin activity, indicative of a volume over-
load in post-infarct GK rats, a feature that was not
present in non-diabetic Wistar rats.
The Akt kinase pathway is activated by various stress-
ful stimuli such as ischemia, heat, angiotensin II and
circulating insulin. A previous study revealed that essen-
tial components of the insulin signaling pathway
upstream of the Akt kinase, such as insulin receptor b,
IRS-1 and GLUT4 protein, were impaired in the GK rat
heart [39] which, at least in theory could affect the abil-
ity of the GK rat heart to respond to stress adequately.
The phosphoinositide 3’-phosphatase [phosphoinositide
and tensin homologue on chromosome 10 (PTEN)],
dephosphorylates mediators of the PI3K signaling path-
way, acting as a negative regulator of the anti-apoptotic
effects of Akt [40-42]. In the present study we found
that MI did not increase Akt phosphorylation in GK
rats. PTEN phosphatase expression was slightly
increased after MI in GK rats which might explain the
decrease in Akt kinase phosphorylation level. Although
Akt phosphorylation was decreased, GK rats showed
pronounced increase in cardiomyocyte hypertrophy sug-
gesting the involvement of non-Akt pathways in the
development of diabetes-induced cardiac hypertrophy in
this model.
FOXO3a is one of the effectors through which Akt
suppresses apoptosis. FOXO3a-phosphorylation by Akt
results in cytoplasm translocation and ubiquitination
and subsequent down regulation of FOXO3a- target
genes [43]. In contrast unphosphorylated FOXO3a is
transported in response to stress into the nucleus
where it induces the transcription of FOXO3a-regu-
lated target genes. Nuclear FOXO3a favors expression
of genes regulating the proapoptotic program [20]. In
the present study, we showed that decreased Akt phos-
phorylation in the post-infarct GK rat myocardium was
associated with a decrease in the phosphorylation of
FOXO3a at Akt-preferred Ser253 amino acid. The
W GK W + MI GK + MI
0
1
2
3 * *
p
3
8
 
P
r
o
t
e
i
n
 
(
o
.
d
)
W GK W + MI GK + MI
0
1
2
3
4
5
6
7
*
#
P
h
o
s
p
h
o
-
p
3
8
 
p
r
o
t
e
i
n
(
o
.
d
)
W GK  W + MI GK + MI
0.000
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.009
C
T
G
F
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
C
T
G
F
/
1
8
S
)
W GK W + MI GK + MI
0.000000
0.000000
0.000001
0.000002
0.000002
0.000002
0.000003
0.000003
0.000004
0.000005
0.000005
0.000006 *
I
L
-
6
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
I
L
-
6
/
1
8
S
)
p38 phospho-p38
Tubulin Tubulin
A
CD
B
Figure 7 Increased p38-phosphorylation in diabetic GK rats 12 weeks after MI. Panel (A) shows an increase in total myocardial p38 protein
expression in post-MI GK and Wistar rats. Panel (B) shows an increase in phosphorylated p38 in GK rats with MI. The lower panels in (A) and (B)
shows representative western blots of total–p38 and phospho-p38 respectively, anti-tubulin was used as loading control. Panel (C) shows the
mRNA expression of connective tissue growth factor (CTGF) in myocardial tissue and (D) shows the mRNA expression of interleukin -6 (IL-6) in
myocardial tissue. Data is presented as means ± SEM; * indicates P < 0.05 vs. W (sham-operated Wistar),
# indicates P < 0.05 vs. GK (sham-
operated GK),
† indicates P < 0.05 vs. W+MI.
Vahtola et al. Cardiovascular Diabetology 2010, 9:5
http://www.cardiab.com/content/9/1/5
Page 10 of 13decrease in phosphorylation was associated with
increased nuclear FOXO3a-translocation and DNA
binding as assessed by electrophoretic mobility shift
assay. These results were associated with an increase
in cardiomyocyte apoptosis in the GK rat heart as
assessed by TUNEL stain. In the remote area and the
area next to the infarct the number of apoptotic cells
w a sh i g h e ri nG Kr a t s .O u rs t u d ys h o w e df u r t h e re v i -
dence of apoptotic post-infarct cardiac remodeling in
GK rats with a marked increase in the protein expres-
sion of key regulators of apoptosis, namely the caspase
-3 and Bax-proteins. Further we showed that collagen
volume fraction was increased in the interstitial tissue
of the GK rat myocardium.
Our study showed that Sirt1 protein was overex-
pressed in both the remote area (posterior wall) and in
the infarct area (anterior wall). Western blotting from
remote area confirmed the result from our earlier stu-
dies [15], that Sirt1 protein was overexpressed in GK
rats. In contrast, Sirt1 protein in post-infarct Wistar rats
was not readily locatable in the infarct area. Further-
more we showed that increased Sirt1 protein in the
remote area was associated with deacetylation of the
Sirt1-target p53 in GK + MI rats. Sirt1 overexpression
has been shown to protect cardiomyocytes from apopto-
sis, increase cellular stress resistance and cause modest
hypertrophy [13,44] suggesting that an increase in Sirt1
protein expression during heart failure may be cardio
protective. Decreased Sirt1- mediated p53-acetylation
has been shown to be associated with a decrease in p53-
mediated apoptosis. According to our results, however
apoptosis was increased in the GK + MI rat heart in
spite of the increased Sirt1-p53 deacetylation, although
modestly with only 0.20% TUNEL-positive cells in the
border zone of GK + MI rats. The increase in caspase-3
and Bax protein expression confirm these results. Taken
together we suggest that Sirt1 may be involved in the
post-MI remodeling process possibly protecting it from
apoptosis but inducing hypertrophy.
In the present study we showed an increase in the
phosphorylation of the p38 MAPK in the diabetic post-
infarct GK rat myocardium. The p38 MAPK has been
shown to be activated by hypoxia, inflammation, trans-
forming growth factor beta and other growth factors as
well as by angiotensin II [21-23]. The exact role of p38
in cardiac dysfunction is unclear. It has been suggested
that long-term activation of p38 is deleterious and that
p38 may accelerate cardiomyocyte growth during the
transition from adaptive to maladaptive cardiac hyper-
trophy [24].
In the present study, the infarct exacerbated cardiac
hypertrophy and fibrosis in the GK rat. While Akt
kinase activation could not explain this effect, the
increase in p38 MAP kinase phosphorylation might have
played a role. Previous studies have indicated an
increase in cardiac fibrosis in response to p38 MAPK
overexpression and shown that adenoviral p38-injection
into the heart increased CTGF mRNA expression [27].
We showed here that in the diabetic heart a higher level
of cardiac collagen deposition was associated with an
increase in p38 phosphorylation in myocardial tissue 12
weeks after MI. P38 MAPK activation has been asso-
ciated with an increase in the expression of pro-inflam-
matory regulators such as interleukin-6 (IL-6),
cyclooxygenase-2 (COX-2) and CCL2 in the heart [27].
In the present study we showed a tendency for IL-6 and
CTGF mRNA expressions to be increased after MI in
diabetic GK rats.
Together these results indicate that markers of stress
response during the stable period of heart dysfunction
are different in the diabetic versus non-diabetic heart. In
GK rats, MI induced an increase in PTEN protein
expression, reduced Akt phosphorylation and a conco-
mitant decrease in FOXO3a phosphorylation which
might have contributed to the increase in cardiomyocyte
apoptosis seen here. We showed that Sirt1 protein over-
expression is sustained after MI in diabetic rats, and
that is localized to the nuclei at the infarct area. Sirt1
protein overexpression was further associated with a
decrease in p53 acetylation in GK rats postligation.
Furthermore our results support the notion that long-
term p38 MAP-kinase activation may increase post-
infarct cardiac remodeling in the diabetic GK rat heart,
promoting an increase in fibrosis, cardiomyocyte hyper-
trophy and an increase in the expression of pro-inflam-
matory regulators. In conclusion post-infarct cardiac
remodeling in diabetic GK rats included increased cardi-
omyocyte hypertrophy, increased cardiomyocyte apopto-
sis and interstitial fibrosis. The present study suggests
an important role for Akt-FOXO3a, Sirt1-p53 and p38
in the regulation of post-infarct cardiac remodeling in
type 2 diabetes.
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